Clinical Trials Browser

Carcinoma, Transitional Cell × enfortumab vedotin × 90 days × Clear all

Carcinoma, Transitional Cell

NCT07484022 2026-03-19

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Not yet recruiting

37 enrolled

Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT04963153 2026-03-18

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Phase 1 Active not recruiting

24 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06862219 2026-03-06

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase 4 Recruiting

100 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07221942 2026-02-19

IMPROEV

Phase 2 Recruiting

97 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Not yet recruiting

132 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06483334 2026-02-18

MK-3475-04C

Phase 1/2 Active not recruiting

38 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05868265 2026-02-17

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2 Recruiting

24 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06724159 2026-02-17

SOGUG-PRINCIS

Recruiting

500 enrolled

Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Clinical Trials

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

IMPROEV

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

MK-3475-04C

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

SOGUG-PRINCIS

Circulating Tumor DNA Response In Urothelial Cancer

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)